Arbor's hospital portfolio grows as Eisai sheds US rights to Gliadel
This article was originally published in Scrip
Eisai is continuing to rationalize operations and hone its focus on major products against a background of revenue pressures, this time through an agreement to divest to Arbor Pharmaceuticals the US rights to Gliadel Wafer (polifeprosan 20 with carmustine implant).
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.